Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expenses for non refundable up front payment for license agreement.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementUpfrontPayment
Namespace Prefix:	vstm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of royalties and milestone payments entitled under any license or sublicense agreements in certain jurisdictions

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions
Namespace Prefix:	vstm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of royalty, milestone and sublicense revenue payments entitled to the company under the existing license and collaboration agreement.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements
Namespace Prefix:	vstm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of regulatory milestone payments receivable under the License and collaboration agreements.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable
Namespace Prefix:	vstm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of regulatory milestone payments receivable up on approval received from the approval for commercial sale under the License and collaboration agreements.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale
Namespace Prefix:	vstm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of regulatory milestone payments receivable up on approval received from the approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma under the License and collaboration agreements.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra
Namespace Prefix:	vstm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of sales milestone receivable under the License and collaboration agreements.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable
Namespace Prefix:	vstm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of threshold sale revenue to be achieved in order for the company to receive the sales milestone payments under the License and collaboration agreements.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments
Namespace Prefix:	vstm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of threshold sale revenue to be achieved in order for the company to receive the royalty payments under the License and collaboration agreements.

+ References

No definition available.

+ Details

Name:	vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments
Namespace Prefix:	vstm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=vstm_SecuraBioInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License, collaboration and commercial agreements - Secura (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2020	Jun. 30, 2026	Jun. 30, 2026
Sale of COPIKTRA license and related assets
License, collaboration and commercial agreements
Revenue recognized		$ 15,000	$ 15,000
License and Collaboration Agreement \| Secura
License, collaboration and commercial agreements
Upfront payment	$ 70,000
Milestone payments receivable upon approval of COPIKTRA	35,000
Milestone payments receivable upon approval for commercial sale	10,000
Threshold sales to trigger royalty payments	$ 100,000
Percentage of all royalty, milestone and sublicense revenue payments payable	50.00%
Percentage of all royalty and milestone payments payable under certain jurisdictions	50.00%
License and Collaboration Agreement \| Secura \| Sale of COPIKTRA license and related assets
License, collaboration and commercial agreements
Milestone payments receivable upon approval of COPIKTRA		15,000	15,000
Sales milestone receivable		$ 15,000	15,000
Revenue recognized			15,000
License and Collaboration Agreement \| Secura \| Sales Exceeds $100 Million
License, collaboration and commercial agreements
Sales milestone receivable	$ 10,000
Threshold sales to trigger milestone payments	100,000
License and Collaboration Agreement \| Secura \| Sales Exceeds $200 Million
License, collaboration and commercial agreements
Sales milestone receivable	15,000
Threshold sales to trigger milestone payments	200,000		200,000
License and Collaboration Agreement \| Secura \| Sales Exceeds $200 Million \| Sale of COPIKTRA license and related assets
License, collaboration and commercial agreements
Threshold sales to trigger milestone payments			200,000
Revenue recognized			$ 15,000
License and Collaboration Agreement \| Secura \| Sales Exceeds $300 Million
License, collaboration and commercial agreements
Sales milestone receivable	25,000
Threshold sales to trigger milestone payments	300,000
License and Collaboration Agreement \| Secura \| Maximum
License, collaboration and commercial agreements
Regulatory milestone payments	45,000
Sales milestone receivable	$ 50,000